TRAW: trawspharma.com Price-to-Projected Revenue Ratio

Graphic logo of Traws Pharma Inc (TRAW)

The forward price-to-sales ratio demonstrates the cost of capital dynamics, where 3.20 represents the latest metric reading. High barriers to entry are created by expensive R&D and FDA oversight. Meanwhile, Traws Pharma, Inc. (TRAW) relies on its debt-free balance sheet and molecule protection, while the development of small-molecule influenza treatments ensures a prolonged commercialization period for its products.

Traws Therapeutics - TRAW Forward P/S Multiple (period 04/04/2024 - 08/17/2026)

Analytical breakdowns for Traws Pharma, Inc.

- stock price and consensus target price:
Stock Quotes Traws Pharma|TRAW - Analyst Forecast Prices
- market capitalization information:
Market Value TRAW|TRAW - Value Adjusted for Debt and Cash
- book value of equity indicators:
Book Value per Share Traws Pharma|TRAW - Book Capitalization|Market Cap to Net Assets Ratio trawspharma.com|TRAW - Cumulative Company Assets
- debt and solvency information:
Debt to Equity Traws Pharma, Inc.|TRAW - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio Traws Pharma|TRAW - Aggregate Debt Obligations|Debt to Book Capitalization Ratio TRAW|TRAW - Long-Term Liabilities|Company Short-Term Debts Traws Pharma|Quick Ratio trawspharma.com
- financial results and valuation multiples details:
TRAW - Net Profit|Expected Profit Traws Pharma, Inc.|TRAW - Company Value to Net Income|Future Price to Earnings Traws Pharma|TRAW - Price/Earnings to Growth Multiple|EV/EBITDA Multiple TRAW|TRAW - Operating profit EBITDA|Net earnings per share for the last 12 months Traws Pharma|TRAW - Earnings per share for the trailing year|Quarterly EPS earnings growth trawspharma.com|TRAW - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Traws Pharma, Inc.
- total revenue and sales volume data:
TRAW - Company Sales Volume|Projected Sales Volume Traws Pharma|TRAW - Market Cap to Revenue|Forward Price-to-Revenue Multiple TRAW
Summary company analysis:TRAW (Traws Therapeutics)
Original product of Traws Pharma Inc

The investor is assessing growth potential by comparing the current market value of Traws Pharma, Inc. (TRAW) with projected revenue based on 10-K and 10-Q filings. This ratio measures the premium for future sales, which, for a developer of unique antiviral drugs with low demand elasticity, reflects market confidence in the business's pricing power, as clearly demonstrated by the expected P/S dynamics.

Direct competitors

Gilead Sciences - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio CDTX (Cidara Therapeutics Corp)|NVAX - Price-to-Projected Revenue Ratio|Forward Price to Sales CVAC (CureVac Pharma)|VALN: Forward P/S Multiple|vir.bio (VIR) - Forward P/S Multiple|Forward Price-to-Revenue Multiple SIGA|Forward Price-to-Revenue Multiple Emergent BioSolutions Inc (EBS)|Price-to-Projected Revenue Ratio Atea Pharmaceuticals Inc (AVIR)|Market Cap to Expected Sales Ratio invivyd.com|Enanta Pharmaceuticals - Forward Price-to-Revenue Multiple|Forward Price to Sales INO|HLVX - Price-to-Projected Revenue Ratio|Future Price to Revenue KLRS|DYAI: Forward P/S Multiple|NanoViricides - Forward Price to Sales|TLPH (Talphera, Inc.) - Forward P/S Multiple|Forward P/S Multiple cocrystalpharma.com|Price-to-Projected Revenue Ratio Dogwood Therapeutics, Inc. (DWTX)|QLGN (Qualigen Therapeutics Inc) - Forward Price to Sales|Price-to-Projected Revenue Ratio AlloVir ALVR|VBIV - Forward Price-to-Revenue Multiple|Virios - Forward P/S Multiple|VXRT - Forward P/S Multiple